The quarter cleared modest expectations. Revenue was $264.2 million versus a published consensus of roughly $263.1 million, while adjusted EPS reached $0.20 against a published estimate near $0.12. That makes this a beat, though not a major top-line surprise. (Financial Highlights)
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Revenue | $264.2M | $251.4M; ~$263.1M consensus |
| Adjusted EPS | $0.20 | $0.08; ~$0.12 consensus |
| GAAP EPS | $0.03 | $(0.10); ~$0.02 consensus |
| Adjusted EBITDA | $56.4M | $56.3M |
| Adjusted EBITDA margin | 21.4% | 22.4% |
| Consolidated advanced procedure growth | 6.8% | — |
The operating engine is growing, but not converting that growth into incremental EBITDA. Consolidated revenue rose 5.1%, and advanced outpatient volumes grew 6.8%, with same-center advanced volume up 5.2%. Yet adjusted EBITDA was essentially flat at $56.4 million, and the margin fell 100 basis points to 21.4%. (Financial Highlights) (Q2 2026 Outpatient Volumes Highlights) (Adjusted EBITDA reconciliation)
The earnings beat was helped by lower financing costs rather than a cleaner operating result. Operating income declined to $23.0 million from $27.7 million as cost of operations and general and administrative expenses grew faster than revenue. Interest expense fell sharply to $16.2 million from $30.1 million, helping net income turn positive at $2.7 million from a $7.2 million loss. (Condensed Consolidated Statements of Operations)
Management left the annual framework intact, which limits the incremental information. Revenue guidance remained $1.045 billion to $1.097 billion, adjusted EPS stayed at $0.71 to $0.77, and the adjusted EBITDA midpoint remained $238 million. The EBITDA range was narrowed from $234 million–$242 million to $235 million–$241 million, but that is refinement rather than a forecast increase. (2026 Full Year Outlook) The company also acknowledged that approximately $7 million of public-company costs reduce expected 2026 adjusted EBITDA growth from 7% to 4% versus 2025. (2026 Full Year Outlook)
Net read: a real but narrow beat, with margin pressure keeping the signal contained. The filing improves the near-term scorecard through better-than-expected EPS and slightly above-consensus revenue, but flat adjusted EBITDA and unchanged guidance do not yet demonstrate stronger full-year earnings power.
Read the original 8-K on SEC EDGAR ↗